Biotech M&A – 2020 Deals

Biotech M&A – 2020 Deals

Biotech M&A With a Slow Start in 2020: More Deals to Follow?

DateAcquirer Co.Acquirer TickerAcquired Co.Acquired TickerDeal valuePrice/ShareCVR (if any)Notes
01/10/2020Eli LillyLLYDermiraDRMA$1.1B$18.75chronic skin conditions
03/03/200GileadGILDForty SevenFTSV$4.9B$95.50CD47 for AML & MDS
05/04/2020Menarini Group-ItalyPrivateStemline TherapeuticsSTML$677M $11.50CVR $1CD123 ELZONRIS Oncology
05/05/2020Alexion PharmaceuticalALXNPortola PharmaceuticalPTLA$1.41B$18CVR $6.00 upon FDA acceptance of the NDA filing (+$263M)Uncontrolled bleeding
Factor Xa inhibitor
08/17/2020SanofiSNYPrincipia BiopharmaPRNB$3.68B$100BTKi for MS
08/19/2020Johnson & JohnsonJNJMomentaMNTA$6.5B$52.20FcRn inhibitor, treatment of autoantibody-driven autoimmune diseases
08/31/2020Nestlé, S.A.part of Nestlé Health Science (NHSc)Aimmune TherapeuticsAIMT$2.6B$34.50PALFORZIA,treatment for food allergy (peanuts)
08/31/2020Ionis PharmaceuticalsIONSAkcea TherapeuticsAKCA$500M$18.15to acquire remaining 24% of common stock
09/13/2020GileadGILDImmunomedics IMMU$21B$88Trodelvy-Breast cancer
09/21/2020IlluminaILMNGRAILPrivate$8B--$3.5B in cash & $4.5B in shares
Cancer Screening Test
10/05/2020Bristol Myers SquibbBMYMyoKardiaMYOK$13.1B$225Mavacamte for Symptomatic Obstructive Hypertrophic Cardiomyopathy
10/05/2020BridgeBio PharmaBBIOEidos TherapeuticsEDIX$2.8B$73.26Either 1.85 shares of BBIO or $73.26 in cash per EDIX
10/19/2020Endo International ENDP BioSpecifics TechnologiesBSTC$658M$88.50injectable collagenase (CCH) portfolio, consisting of XIAFLEX
10/26/2020BayerBAYRYAsklepios BioPharmaceuticalPrivate$2.0B-AAV Gene Therapy
10/27/2020Exact SciencesEXASThrive Earlier DetectionPrivate$2.15B-Liquid Biopsy
11/02/2020SanofiSNYKiadis Pharma N.V.KIADF€308 million€4.54NK-cell-based medicines
11/05/2020MerckMRKVelosBioPrivate$2.74B-cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1)
11/06/2020Novo NordiskNVOEmisphere TechnologiesEMIS$1.35B$7.82drug delivery technology Eligen
11/12/2020Sumitovant BiopharmaPrivateUrovant Sciences UROV$584M$16.25vibegron pending FDA approval
11/23/20202MerckMRKOncoImmunePrivate$425MCD24Fc treatment of severe & critical COVID-19.

For M&A 2019 full table click here https://www.chimeraresearchgroup.com/biotech-ma-2019-deals/

Recent Press

Slider

Log In

JoinLost Password?